Phase II Study Evaluating the Safety and Efficacy of TXA127 in the Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant in Patients With Hodgkin Lymphoma, Non-Hodgkin Lymphoma or Multiple Myeloma Undergoing Limited Reinfusion of CD34+ Cells
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Angiotensin-1-7 (Primary)
 - Indications Hodgkin's disease; Multiple myeloma; Non-Hodgkin's lymphoma
 - Focus Adverse reactions; Therapeutic Use
 - Acronyms TXA127-PBSC
 - Sponsors Tarix Pharmaceuticals
 
Most Recent Events
- 07 Dec 2020 Status changed from active, no longer recruiting to discontinued.
 - 08 Oct 2020 Planned End Date changed from 1 Sep 2020 to 1 Mar 2022.
 - 08 Oct 2020 Planned primary completion date changed from 1 Jun 2020 to 1 Dec 2021.